Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia

[1]  M. Hallek.  Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment , 2019, American journal of hematology.

[2]  S. Malek,et al.  Chronic Lymphocytic Leukemia , 2019, Methods in Molecular Biology.

[3]  F. Stingo,et al.  Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. , 2016, Blood.

[4]  H. Döhner,et al.  Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. , 2016, Blood.

[5]  R. Foà,et al.  Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. , 2015, Blood.

[6]  M. Hallek.  Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment , 2015, American journal of hematology.

[7]  T. Fukuda.  [Pathogenesis of chronic lymphocytic leukemia]. , 2015, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[8]  T. Shanafelt,et al.  CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Montserrat,et al.  New treatment options for chronic lymphocytic leukemia , 2014, Expert opinion on pharmacotherapy.

[10]  S. Carter,et al.  Clonal evolution in hematological malignancies and therapeutic implications , 2014, Leukemia.

[11]  N. Chiorazzi.  Implications of new prognostic markers in chronic lymphocytic leukemia. , 2012, Hematology. American Society of Hematology. Education Program.

[12]  Richard Sherry,et al.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.

[13]  Robert Busch,et al.  Isolation of malignant B cells from patients with chronic lymphocytic leukemia (CLL) for analysis of cell proliferation: validation of a simplified method suitable for multi-center clinical studies. , 2010, Leukemia research.

[14]  Rob J. De Boer,et al.  Explicit Kinetic Heterogeneity: Mathematical Models for Interpretation of Deuterium Labeling of Heterogeneous Cell Populations , 2009, PLoS Comput. Biol..

[15]  N. Chiorazzi,et al.  In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. , 2009, Blood.

[16]  L. Willems,et al.  Measurement of ribosomal RNA turnover in vivo by use of deuterium-labeled glucose. , 2009, Clinical chemistry.

[17]  Nienke Vrisekoop,et al.  In vivo dynamics of stable chronic lymphocytic leukemia inversely correlate with somatic hypermutation levels and suggest no major leukemic turnover in bone marrow. , 2008, Cancer research.

[18]  A. Burny,et al.  Reduction of B cell turnover in chronic lymphocytic leukaemia , 2008, British journal of haematology.

[19]  Sonia Jain,et al.  Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. , 2008, Blood.

[20]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[21]  M. Hellerstein,et al.  Measurement of very low rates of cell proliferation by heavy water labeling of DNA and gas chromatography/pyrolysis/isotope ratio–mass spectrometric analysis , 2007, Nature Protocols.

[22]  E. Montserrat,et al.  Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. , 2005, Blood.

[23]  S. Turner,et al.  Physiologic and Pharmacologic Factors Influencing Glyceroneogenic Contribution to Triacylglyceride Glycerol Measured by Mass Isotopomer Distribution Analysis* , 2005, Journal of Biological Chemistry.

[24]  Marc K Hellerstein,et al.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. , 2005, The Journal of clinical investigation.

[25]  Arthur Weiss,et al.  ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. , 2004, The New England journal of medicine.

[26]  Becca Asquith,et al.  Lymphocyte kinetics: the interpretation of labelling data. , 2002, Trends in immunology.

[27]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[28]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[29]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[30]  L. Rassenti,et al.  Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. , 1998, The Journal of clinical investigation.

[31]  Mark J. Thomas,et al.  A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.

[32]  D C Case,et al.  Clinical staging of chronic lymphocytic leukemia. , 1977, The Journal of the Maine Medical Association.

[33]  S. Perry,et al.  Studies of leukocyte kinetics in chronic lymphocytic leukemia. , 1968, Blood.

[34]  W. Dameshek.  Special Article: Chronic Lymphocytic Leukemia—an Accumulative Disease of Immunologically Incompetent Lymphocytes , 1967 .

[35]  W. Dameshek.  Chronic lymphocytic leukemia--an accumulative disease of immunolgically incompetent lymphocytes. , 1967, Blood.